A Phase I Study of Concurrent Abemaciclib and Radiation Therapy (RT) for Patients With Metastatic Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Breast Cancer.

A Phase I clinical trial, NCT06678269, is being conducted to determine the optimal dose of abemaciclib in combination with hormone therapy and radiation therapy for patients with metastatic hormone receptor positive, HER2 negative breast cancer. The trial aims to establish the maximum tolerated dose of abemaciclib in conjunction with radiation therapy. The study is interventional, with a primary focus on treatment, and is currently not recruiting participants. The trial is being led by Memorial Sloan Kettering Cancer Center in collaboration with Eli Lilly and Company. [Extracted from the article]